Skip to content
lifestyle.serversfree.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioAge Labs, Inc.
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
June 16, 2026
BioAge Labs to Present at Upcoming Investor Conferences
May 24, 2026
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
May 20, 2026
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
May 16, 2026
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
May 11, 2026
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
April 28, 2026
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
March 24, 2026
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
January 21, 2026
BioAge Announces Proposed Public Offering
January 20, 2026
1
2
Next Page
→